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ORIGINAL ARTICLE
Chronic Kidney Disease Increases Cerebral Microbleeds
in Mouse and Man
Wei Ling Lau1,2 & Ane C. F. Nunes1 & Vitaly Vasilevko3 & David Floriolli4 & Long Lertpanit1 & Javad Savoj1 &
Maria Bangash1 & Zhihui Yao1,5 & Krunal Shah6 & Sameen Naqvi1 & Annlia Paganini-Hill6 & Nosratola D. Vaziri1 &
David H Cribbs3 & Mark Fisher6,7
Abstract
Brain microbleeds are increased in chronic kidney disease (CKD) and their presence increases risk of cognitive decline
and stroke. We examined the interaction between CKD and brain microhemorrhages (the neuropathological substrate of
microbleeds) in mouse and cell culture models and studied progression of microbleed burden on serial brain imaging
from humans. Mouse studies: Two CKD models were investigated: adenine-induced tubulointerstitial nephritis and
surgical 5/6 nephrectomy. Cell culture studies: bEnd.3 mouse brain endothelial cells were grown to confluence, and
monolayer integrity was measured after exposure to 5–15% human uremic serum or increasing concentrations of urea.
Human studies: Progression of brain microbleeds was evaluated on serial MRI from control, pre-dialysis CKD, and
dialysis patients. Microhemorrhages were increased 2–2.5-fold in mice with CKD independent of higher blood pressure
in the 5/6 nephrectomy model. IgG staining was increased in CKD animals, consistent with increased blood–brain
barrier permeability. Incubation of bEnd.3 cells with uremic serum or elevated urea produced a dose-dependent drop
in trans-endothelial electrical resistance. Elevated urea induced actin cytoskeleton derangements and decreased claudin-5
expression. In human subjects, prevalence of microbleeds was 50% in both CKD cohorts compared with 10% in age-
matched controls. More patients in the dialysis cohort had increased microbleeds on follow-up MRI after 1.5 years. CKD
disrupts the blood–brain barrier and increases brain microhemorrhages in mice and microbleeds in humans. Elevated
urea alters the actin cytoskeleton and tight junction proteins in cultured endothelial cells, suggesting that these mech-
anisms explain (at least in part) the microhemorrhages and microbleeds observed in the animal and human studies.
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Introduction
One of the most significant stroke neurology discoveries in
recent years is the emergence of chronic kidney disease
(CKD) as an independent risk factor for early cognitive de-
cline and cerebrovascular disease (reviewed in [1]), especially
cerebral microbleeds and stroke [2–9]. While CKD and cere-
brovascular disease share common risk factors, CKD appears
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to have an impact that goes well beyond traditional risk factors
such as hypertension and diabetes [10, 11]. Given the high
prevalence (about 50%) of cerebral microbleeds and cognitive
impairment in patients with advanced CKD [2–4, 6, 7], this
relationship deserves further study.
Cerebral microbleeds are small foci of hemosiderin–iron
demonstrable on magnetic resonance imaging (MRI), be-
lieved to reflect underlying cerebral microhemorrhages
[12, 13], and indicative of heightened risk for stroke, both
hemorrhagic and ischemic [9, 14]. Specific MRI sequences
(gradient echo and susceptibility-weighted imaging) dem-
onstrate these focal areas of signal loss in brain parenchy-
ma measuring ≤ 10 mm [12, 15]. Cerebral microbleeds are
age-dependent, with prevalence approaching 20% by age
65 [16]. In addition to age, hypertension and cerebral am-
yloid angiopathy are the best described risk factors for
development of microbleeds [13, 17]. In late-stage CKD,
microbleeds are present in up to 50% of the population
[2–4].
Concurrently, cognitive impairment is both more prev-
alent and more severe at lower levels of kidney function
[18], reaching a prevalence of 30–70% in chronic dialysis
patients [6, 7]. In a cross-sectional analysis of 338 hemo-
dialysis patients aged 55 years and older with age-
matched controls, 34% of dialysis patients had severe
cognitive impairment compared with 12% of controls
[6]. Another 35% of the dialysis cohort had moderate
cognitive impairment [6].
Several studies in non-CKD cohorts have demonstrated
a strong association between cerebral microbleeds and
declining cognitive function [19–22]. Epidemiologic data
support co-existence of MRI microbleed burden and cog-
nitive dysfunction in end-stage renal disease (ESRD) pa-
tients [8, 23]. Moreover, a recent report of 28 chronic
dialysis patients with serial brain MRI showed an associ-
ation between new microbleeds and decline in mini-
mental state examination (MMSE) score [4]. Further,
ESRD patients have a 3- to 4-fold higher incidence rate
of both ischemic and hemorrhagic strokes compared with
the general population [5]. In a cohort of Japanese hemo-
dialysis patients who were stroke-free at baseline, the
presence of cerebral microbleeds was an independent pre-
dictor of intracerebral hemorrhage during a 5-year follow-
up period [9].
Here we report results from studies in mice and in CKD
patients.We found increased brain microhemorrhages in CKD
mice and describe impaired endothelial tight junction and ac-
tin cytoskeleton disruption as potential mechanisms for
microhemorrhage formation in the CKD mil ieu.
Retrospective analysis of serial brain MRI from non-CKD,
pre-dialysis and chronic hemodialysis subjects confirmed
ESRD as a significant risk factor for progression of
microbleed burden.
Methods
Mice Experiments
Experimental Animals and Treatment Groups
Two CKD mouse models were investigated. (1) Adenine
tubulointerstitial nephritis model: Male C57BL/6J mice
from Jackson Laboratories (Bar Harbor, ME) aged 10–
12 weeks were fed a diet containing 0.2% adenine for
18 days to induce chronic interstitial nephropathy,
placed back on regular chow for 2 weeks, and then
re-exposed to adenine diet for 1 week to maintain
CKD (Fig. 1a). Control mice were maintained on regu-
lar chow. (2) 5/6 nephrectomy model: Male C57BL/6J
mice aged 10 weeks underwent two-stage surgery at
Jackson Laboratories that involved left partial nephrec-
tomy followed by right total nephrectomy 1 week later.
Animals were delivered to the lab 1 week after the
second surgery. These two models were utilized to de-
termine effect of hypertension; hypertension is a hall-
mark of the 5/6 nephrectomy model, whereas adenine-
CKD is non-hypertensive [24].
CKD animals were randomized to no lipopolysaccha-
ride (LPS) or LPS injections. (In pilot studies, we de-
termined that a longer duration of uremia was needed to
detect higher burden of spontaneous microhemorrhages
in non-treated CKD animals; mice on adenine diet for
only 10 days beyond initial 18 days exposure had 3.0 ±
0.4 microhemorrhages per cm2.)
Five weeks after initial CKD induction and at an
equivalent age in controls, mice were given intraperito-
neal (i.p.) LPS injections (Salmonella enterica serotype
typhimurium, L6511-10MG, Sigma-Aldrich, St. Louis,
MO) to induce brain microbleeds. LPS was adminis-
tered in three doses, 1 mg/kg at 0, 6, and 24 h [25].
LPS-treated mice were given hydration with subcutane-
ous saline injections two-to-three times per day for
3 days after LPS treatment. Blood pressure (BP) was
measured 2 days before LPS injections via tail-cuff
plethysmography (CODA-S2 multi-channel, Kent
Scientific). All experiments were approved by the
University of California, Irvine Institutional Animal
Care and Use Committee.
Tissue Harvest and Blood Chemistries
Mice were euthanized 1 week after LPS injections or at
an equivalent age in non-treated animals by exsanguina-
tion using cardiac puncture under inhaled isoflurane an-
esthesia. A 26-gauge needle was used as a cannula and
inserted into the left ventricle, and ice-cold PBS solu-
tion was applied at a flow rate of 7–8 ml/min. After
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perfusion for 5 min, the left brain hemisphere was snap
frozen for Western blot. The right brain hemisphere and
both kidneys were fixed overnight in 4% paraformalde-
hyde and then stored in cold PBS prior to sectioning.
Serum was aliquoted for blood chemistries. Blood urea
nitrogen (BUN) was measured using the colorimetric kit
from BioAssay Systems (Hayward, CA). Serum creati-
nine was measured using capillary electrophoresis at the
O’Brien Kidney Research Core Center (UT Southwestern,
Dallas, TX).
Detection of Microhemorrhages
The brains were mounted in 1.5% agarose and sectioned
with a vibratome to generate coronal sections (40 μm).
Every 5th section was collected for Prussian blue staining
to detect microhemorrhages [26]. Prussian blue staining
was performed using freshly prepared 5% potassium
hexacyanoferratetrihydrate and 10% hydrochloric acid.
Twenty minutes later, sections were rinsed in water and
counterstained with nuclear fast red, dehydrated, and
coverslipped. Microhemorrhages were identified at × 20
magnification as purple-blue deposits counted by three
independent observers, and then the mean was calculated.
Images of the observed positively stained sections were
captured using a photomicroscope (Nikon Eclipse, Japan)
for three animals per group to calculate microhemorrhage
area. Whole slide images were scanned and the free
ImageJ software (version 10.2) from the National
Institutes of Health (www.imagej.nih.gov/ij/) was used to
calculate total brain surface area. The number of
microhemorrhages was normalized to total brain surface
area per animal.
Western Blotting
Brain hemispheres for protein analysis were snap frozen
at time of tissue collection and homogenized in ice-cold
Tissue Extraction Reagent I (Thermo Fisher Scientific)
supplemented with protease inhibitor cocktail (Roche
Applied Science, Indianapolis, IN). Protein concentrations
were measured with a BCA protein assay kit (Thermo
Fisher Scientific). SDS-PAGE gel electrophoresis was
done with 100 μg of protein per sample. Proteins were
transferred onto PVDF membranes and then blocked for
1 h in 5% non-fat dry skim milk prepared in TBS-T buffer
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Fig. 1 a Experimental timeline for chronic kidney disease (CKD) mice
treated with lipopolysaccharide (LPS) injections to induce brain
microbleeds. Adenine-CKD: Mice were placed on 0.2% adenine diet
for 18 days, followed by regular chow for 2 weeks, then re-exposed to
adenine diet for 1 week to maintain CKD. Two weeks after adenine re-
exposure, LPS 1 mg/kg i.p. injections were given at 0, 6 and 24 h.
Nephrectomy-CKD: 4.5 weeks after 5/6 nephrectomy, LPS 1 mg/kg i.p.
injectionswere given at 0, 6, and 24 h. Subcutaneous saline hydrationwas
given for 3 days after LPS injections. Tail blood pressure (BP) was mea-
sured prior to LPS injections. Mice were sacrificed 1 week after LPS
injections. b Representative H&E stained kidney sections demonstrating
adenine-induced tubulointerstitial injury CKD mice (right panel) com-
pared with normal kidney from CTL animal (left panel), × 20 magnifica-
tion. Scale bar = 100 μm
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(10 mM Tris–HCl, 150 mM NaCl, and 0.1% Tween-20)
and incubated with primary antibodies targeting claudin-5
(diluted 1:200, Sigma-Aldrich SAB4502981), occludin
(diluted 1:200, Invitrogen 711500, Thermo Fisher
Scientific), and normalized to GAPDH internal control
(diluted 1:10,000, Abcam, Cambridge, MA) in 5% non-
fat milk TBS-T overnight at 4 °C. The blots were then
incubated with the respective anti-rabbit or anti-mouse
secondary antibodies for 2 h at room temperature. After
washing with TBS-T, bands were detected using the
Luminescent Image Analyzer LAS-3000 (Fujifilm Life
Science, Stamford, CT).
Immunohistochemistry
To detect blood–brain barrier (BBB) leakage, sections
were incubated with biotinylated anti-mouse IgG second-
ary antibody at 1:100 for 1 h in room temperature (Vector
Laboratories, Burlingame, CA, USA). Following washing
with PBS, sections were incubated for 30 min with avi-
din–biotin–peroxidase complex (Vector Laboratories) at a
dilution of 1:200. Staining was developed using 3′,3′-
diamionbenzidine (DAB, Vector Laboratories) as chromo-
gen. Percent area stained with IgG was analyzed using
ImageJ software in non-LPS CTL and CKD brains. A
threshold for positive IgG staining was chosen by manu-
ally evaluating a control animal for IgG staining, and this
threshold was then kept equal for all included animals
[27].
Cell Culture Experiments
Brain Endothelial Cell Culture and Serum Treatment
Immortalized mouse bEnd.3 cells were purchased from
the American Type Culture Collect ion (ATCC,
Manassas, VA). Endothelial cell phenotype was con-
firmed via immunostaining for von Willebrand factor.
Cell cultures were incubated in high-glucose complete
Dulbecco’s modified Eagle’s medium (DMEM, ATCC
30-2002) containing 25 mM glucose supplemented with
10% fetal bovine serum (FBS) and 1% penicillin–
streptomycin in a humidified incubator at 37 °C in an
atmosphere of 5% CO2 and 95% air. Cells were used at
passage 5 for all experiments. The cells were seeded at
5 × 106 density on 12-well polyester Transwell inserts
(0.4 μm pore, Costar) and confluence was achieved at
24–48 h. Culture medium was then changed to expose
cells to different concentrations of FBS, human normal
serum (HNS), or uremic serum (CKD) from dialysis
patients. TEER readings were measured using the
EVOM2 volt/Ohm Meter (World Precision Instruments,
Sarasota, FL) at three locations per well to obtain an
average. Experiments continued for 21 days, and culture
medium was refreshed every 3–4 days. NHS and uremic
serum were from previously banked samples obtained
after IRB approval and informed consent.
Urea Cell Culture Experiments
To examine effects of urea (the most abundant retained
toxin in CKD), bEnd.3 cells were incubated in high glu-
cose DMEM with 10% FBS alone or in medium supple-
mented with 42 or 72 mg/dL (70 or 120 μm) urea (Sigma-
Aldrich). These urea concentrations approximate the pre-
and post-hemodialysis values generally found in ESRD
patients, and are considered to be clinically relevant
[28]. At the conclusion of a 24-h incubation period, the
TEER was measured and cells were harvested and proc-
essed for Western blot analysis. For visualization of the
actin cytoskeleton, bEnd.3 cells were grown on glass cov-
er slips and exposed to the above urea concentrations for
24 h, fixed for 10 min in chilled 4% formalin/PBS and
then processed for immunofluorescence staining using
acti-stain 488 fluorescent phalloidin with DAPI nuclear
stain (catalog# PHDG1-A, Cytoskeleton Inc., Denver,
CO). Triplicate slides were done per group, and three
frames were imaged per slide on ImageJ software to cal-
culate area of phalloidin staining normalized to DAPI
area.
Western Blotting
bEnd.3 cells from the urea experiments were pelleted,
then lysed in Tissue Extraction Reagent I (Thermo
Fisher Scientific) supplemented with protease inhibitor
cocktail (Roche Applied Science). Protein concentrations
were measured with a BCA protein assay kit, and
Western blotting was done as described above with
claudin-5 (diluted 1:500) and occludin (diluted 1:500)
normalized to GAPDH internal control (diluted
1:20,000). Western blots were repeated at least three
times for each sample.
Human Studies
Retrospective Brain MRI Chart Review
Electronic medical records between January 1, 2008 and
December 31, 2014 at University of California-Irvine
Medical Center were screened using the Honest Broker
system and UCReX (University of California Research
Exchange) after IRB approval. Pre-dialysis CKD (n = 8)
and chronic hemodialysis patients (n = 9) who had at
least two brain MRI scans at separate time points were
identified (of 10 hemodialysis patients initially
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identified, 1 was removed from final analysis due to
missing images in the radiology PACS system).
Controls with normal kidney function (n = 10) were
manually matched to the hemodialysis CKD patients
by gender and age ± 5 years.
Review of MRI for Cerebral Microbleeds
Microbleeds were counted by an attending neuroradiolo-
gist (DF) and analyzed for progression over time. Brain
MRI with T2*-weighted and susceptibility-weighted im-
aging (SWI) and FLAIR (fluid attenuated inversion recov-
ery) images were performed on 1.5T and 3T MRI scan-
ners. Layer thickness for SWI sequences was performed at
2 mm, with an interlayer interval of 0. Microbleeds were
counted based on 2-mm axial SWI. FLAIR was per-
formed to detect white matter lesions at 3 mm slice thick-
ness, also with an interlayer interval of 0.
Statistical Analysis
There were no data outliers upon screening with the Grubbs’
test (extreme studentized deviate method, http://graphpad.
com/quickcalcs/grubbs1/). Differences among groups in
mouse and in man were compared by chi-square (Fisher’s
exact) tests for categorical variables and t tests and ANOVA
for continuous variables. Continuous data are reported as
mean ± SEM. For mouse data, we performed both a
Kruskal–Wallis non-parametric and a one-way ANOVAwith
Tukey HSD tests. Two-way ANOVA (CKD-yes/no and LPS-
yes/no) was used to test CKD interaction. Differences among
groups were considered significant if P < 0.05. Figures were
generated using GraphPad Prism 4 software (GraphPad
Software, San Diego CA).
Results
Survival with LPS Treatment
CKD mice treated with LPS had a 80% suvival rate. Only
mice that survived to 1 week after LPS treatment were
included in the final analyses. All mice in other groups
survived to the end of the experiment.
CKD Significantly Increased Brain Microhemorrhages
Burden After LPS Treatment
Animals with adenine-induced and 5/6 nephrectomy CKD
showed significantly elevated blood urea nitrogen (BUN) and
serum creatinine values compared with CTL animals (Table 1).
Tail BP was significantly higher in nephrectomy-CKD animals
comparedwith CTL and adenine-CKD animals (Table 1); how-
ever, microbleed counts in the two CKD groups were similar.
H&E staining confirmed adenine-induced tubulointerstitial in-
jury in the kidneys from CKD mice (Fig. 1b).
Mean brain microhemorrhage burden was 2.0 ± 0.5 per cm2
in non-LPS CTL mice and was increased 2–2.5-fold in non-
LPS CKD animals (adenine-CKD mice 4.5 ± 0.9 per cm2;
nephrectomy-CKD mice 4.2 ± 1.1 per cm2) (Table 1; Fig. 2a).
For the non-LPS groups, increase in microhemorrhages was
significant for adenine-CKD compared with CTL but not for
nephrectomy-CKD. LPS treatment increasedmicrohemorrhage
formation to the same degree in CTL and CKD animals by
Table 1 Animal studies
Group n Body weight at termination (g) Tail systolic BP (mmHg) Serum creatinine (mg/dL) Microhemorrhage quantitation
(count per cm2)
CTL 8 29.7 ± 0.5 111 ± 3.7 0.1 ± 0.001 2.0 ± 0.5
BUN: 33.2 ± 1.7
CTL+LPS 11 28.9 ± 0.5 -- 0.09 ± 0.002 3.6 ± 0.4
Ad-CKD 9 26.6 ± 0.3 # 113 ± 4.3 0.42 ± 0.019 # 4.5 ± 0.9
BUN: 99.5 ± 8.2 #
Ad-CKD+LPS 11 25.1 ± 0.6 # -- 0.29 ± 0.008 # 10.3 ± 1.5 #*
Neph-CKD 5 25.2 ± 0.5 # 127 ± 3.3 # 0.27 ± 0.022 # 4.2 ± 1.1
BUN: 124 ± 15 #
Neph-CKD+LPS 10 26.8 ± 0.6 # -- 0.28 ± 0.022 # 8.8 ± 2.5 #
ANOVA p-value < 0.05 < 0.01 < 0.05 < 0.01
Bodyweights, tail blood pressure (BP), serum biochemistries including BUN (blood urea nitrogen, mg/dL) and microhemorrhage quantitation of control
(CTL) and chronic kidney disease (CKD) mice treated with intraperitoneal lipopolysaccharide (LPS) to induce brain microhemorrhages. Two models of
CKDwere examined: adenine tubulointerstitial nephritis (Ad-CKD) and 5/6 nephrectomy (Neph-CKD). Data shown as mean±SEM, #P<0.05 compared
with CTL, *P<0.05 compared with CTL+LPS
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approximately 2-fold, P = 0.004. Microhemorrhages were pre-
dominantly distributed in the cerebellum, cortex, and sub-
cortex as described previously [26]. The adenine-CKD + LPS
group had the highest mean microhemorrhage count of 10.3 ±
1.5 per cm2. Morphology and size distribution of
microhemorrhages were similar between CTL and CKD ani-
mals (Fig. 2b) with a trend for larger average microhemorrhage
area in LPS-treated CKDmice (0.001 mm2 in CTL, 0.005mm2
in CTL + LPS, 0.004 mm2 in adenine-CKD, 0.013 mm2 in
adenine-CKD + LPS, 0.004 mm2 in nephrectomy-CKD, and
0.021 mm2 in nephrectomy-CKD + LPS, P = 0.24).
BBB function was evaluated by mouse IgG staining in the
non-LPS animal groups. The percent area stained with IgG
above the pre-set threshold intensity was significantly in-
creased in CKD animals, 42 ± 9% compared with 4 ± 3% in
CTL mice (Fig. 2c). Expression of claudin-5 and occludin
tight junction proteins were significantly decreased in the
brains of CKD mice (Fig. 2d).
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Fig. 2 a Brain microhemorrhage burden was doubled in CKD mice
compared with CTL animals, and LPS treatment increased
microhemorrhage count. #P < 0.05 compared with CTL, *P < 0.05
compared with CTL + LPS (data analyzed using one-way ANOVA). b
Representative brain micrographs demonstrating parenchymal
microhemorrhage in a CTL mouse (left), CTL + LPS mouse (middle),
and adenine-CKD + LPS mouse (right), × 40 magnification.
c Representative coronal brain sections from control (left) and CKD
(right) mice. Increased blood–brain barrier permeability in CKD animal
was evidenced by increased IgG staining. d Western blot data demon-
strating decreased expression of tight junction proteins in brain tissue
lysates from two CKD mouse models, adenine tubulointerstitial nephritis
(Ad-CKD) and 5/6 nephrectomy (Neph-CKD) (P < 0.05 compared with
controls, CTL)
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Exposure to Uremic Serum Decreased TEER and Tight
Junction Protein Expression
Treatment of bEnd.3 cells with 5%, 10%, or 15% CKD
serum from hemodialysis patients produced a marked
drop in trans-endothelial electrical resistance (TEER)
that was most pronounced at 12 h, when TEER was
74%, 69%, and 61% in the 5%, 10%, and 15% CKD
groups respectively compared with 10% FBS control
values (Fig. 3a), i.e., there was a dose-dependent
TEER decline.
The chronic effects of serum treatment (21 days) (Fig. 3b)
showed an increase in TEER values in the CKD groups over
time suggesting repair of the junctional barrier. However, the
TEER readings in all three CKD groups remained significant-
ly lower at 21 days compared with the FBS groups (for exam-
ple, 21-day TEER for the 5% CKD group was 88% of the
TEER noted in 5% FBS group).
Exposure to Elevated Urea Alone Decreased TEER
in Conjunction with Actin Cytoskeleton
Derangements and Decreased Tight Junction Protein
Expression
Treatment of confluent bEnd.3 cells with 0, 42, or 72 mg/dL
urea in DMEM with 10% FBS resulted in a concentration-
dependent drop in TEER (Fig. 4a). The tight junction proteins
claudin-5 and occludin were decreased ~ 25% after 24-h ex-
posure to the highest urea concentration, with the drop in
claudin-5 reaching statistical significance (Fig. 4b). Urea ex-
posure was associated with disruption of the actin cytoskele-
ton as visualized by phalloidin immunofluorescence (Fig. 4c).
Phalloidin staining was significantly decreased in the 72 mg/
dL urea group compared with the reference zero urea group
(P < 0.05). Cells remained viable as evidenced by unchanged
trypan blue exclusion and maintained endothelial phenotype
on immunostaining for von Willebrand factor.
Fig. 3 Incubation of bEnd.3 mouse brain endothelial cells with 5%, 10%,
or 15% of fetal bovine serum (FBS) vs. human normal serum (HNS) vs.
chronic kidney disease (CKD) serum from hemodialysis patients. a
Treatment of bEnd.3 cells with CKD serum produced a marked drop in
trans-endothelial electrical resistance (TEER) that was most pronounced
at 12 h. Data are mean ± SEM; #P < 0.05 in CKD compared with FBS
groups, *P < 0.05 in CKD compared with HNS groups, †P < 0.05 across
CKD groups (dose effect). b The experiment was extended to 21 days to
study chronic effects of serum treatment, and culture medium was
refreshed every 3–4 days. The asterisk notation next to day number on
the x-axis indicates days on which medium was refreshed. TEER values
in the CKD groups showed an increase over time, suggesting repair of
tight junction barrier under chronic uremic conditions. However, TEER
remained significantly lower at 21 days compared with the FBS groups
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Microbleed Progression on BrainMRIsWas Significant
in Chronic Hemodialysis Patients
In a retrospective analysis of serial brain MRIs, one third to
half of the CKD cohorts (4/8 of pre-dialysis and 3/9 of dialysis
participants) had microbleeds on the first MRI compared with
1/10 patients in the non-CKD group (Table 2). From chart
review, most of the ESRD cases were due to diabetic
nephropathy and hypertension (4); other causes included lu-
pus nephritis (2), hypertension (1), IgA nephropathy vs. lupus
nephritis (1), and cystinosis (1). Figure 5 shows representative
brain MRI images (SWI and FLAIR) from a chronic hemodi-
alysis patient who developed new microbleed and lacunar
infarct lesions on follow-up imaging.
Two of three dialysis patients showed progression of
microbleed burden at follow-up. One dialysis patient who had
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Fig. 4 Treatment of bEnd.3 mouse brain endothelial cells with 0, 42, or
72 mg/dL of urea for 24 h. a Trans-endothelial electrical resistance
(TEER) was significantly decreased with the 72 mg/dL urea exposure.
#P < 0.05 (0 h vs. 24 h); *P < 0.05 (− 24 h vs. 24 h). b There was dose-
dependent decrease in expression of the tight junction proteins claudin-5
and occludin with increasing urea concentrations, one-way ANOVA
P < 0.05 for the claudin-5 dataset and P = 0.1 for the occludin dataset.
#P < 0.05 compared with 0 mg/dL urea group. c bEnd.3 cells exposed to
urea demonstrated derangement and decreased expression of the F-actin
cytoskeleton. Immunofluorescence staining done with acti-stain 488 fluo-
rescent phalloidin (green pseudo-color) and DAPI nuclear stain (blue).
Yellow arrows represent cortical fibers, dashed yellow arrows represent
fragmented cortical fibers, and red arrows represent radial stress fibers.
#P < 0.05 compared with 0 mg/dL urea group
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zero microbleeds on first MRI had new microbleeds on follow-
up imaging. In contrast, microbleed number was unchanged in
all pre-dialysis patients. The difference in proportion that
progressed over follow-up period among the three groups was
statistically significant (P = 0.03). There was no statistically
significant difference in mean age, mean follow-up months,
or proportion that were male, but power was limited by the
small sample size. We found no association between
SWI 
occipital lobes   
FLAIR 
lateral ventricles 
SWI  
lateral ventricles  
a b
c d
e f
Fig. 5 Representative magnetic
resonance images showing
progression of brain pathology in
a chronic hemodialysis patient.
The patient had imaging done in
2010 (images A, C, and E) and in
2011 (images B, D, and F). (A, B)
SWI (susceptibility-weighted
imaging) at the level of the oc-
cipital lobes demonstrate an in-
terval microbleed within the right
occipital lobe (white arrow). (C,
D) FLAIR (fluid attenuated in-
version recovery) images at the
level of the lateral ventricles
demonstrate an interval lacunar
infarction of the left
periventricular white matter
(white arrow). (E, F) SWI images
through the lateral ventricles
demonstrate blood products asso-
ciated with this lesion, compatible
with a hemorrhagic infarction or
microinfarction
Table 2 Human studies retrospective analysis of serial MRIs
demonstrated progression of microbleed burden in 3/9 chronic hemodi-
alysis patients vs. 0/10 and 0/8 in the non-CKD controls and pre-dialysis
CKD cohorts respectively (†P = 0.03 per Fisher’s exact test). Data shown
as mean ± SEM where appropriate
Group n Age (years) % Male Hypertension
comorbidity
No. of microbleeds on
first and second MRI
No. of months follow-up No. of patients with
microbleed progression
Controls 10 55.5 ± 5.3
20%
30% 1 ➔ 1 (n = 1)
0 ➔ 0 (n = 9)
19.5 ± 5.6 0 of 1
Pre-dialysis CKD 8 63.1 ± 4.4
50%
75% 1 ➔ 1 (n = 3)
2 ➔ 2 (n = 1)
0 ➔ 0 (n = 4)
16.0 ± 3.3 0 of 4
Dialysis CKD 9 52.6 ± 6.4
11%
89% 7 ➔ 7 (n = 1)
7 ➔ 13 (n = 1)
12 ➔ 13 (n = 1)
0 ➔ 268 (n = 1)
0 ➔ 0 (n = 5)
18.4 ± 3.9 3 of 4†
†P = 0.03 Fisher’s exact test for proportion with microbleed progression
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hypertension comorbidity and presence of microbleeds in
the dialysis cohort; four of four patients with microbleeds
detected on MRI had history of hypertension vs. four of
five patients with zero microbleeds at baseline and at fol-
low-up.
Discussion
In this paper, we report an increased prevalence of cere-
bral microhemorrhages in CKD mice and of microbleeds
in CKD patients. CKD animals had evidence of BBB
disruption, and cerebral microhemorrhages were increased
over 2-fold compared with control mice. In the human
study, ~ 50% of CKD patients (both in pre-dialysis and
dialysis groups) had MRI-demonstrable microbleeds com-
pared with 10% of controls. In our mouse studies, the
highest microhemorrhage load was observed with LPS
treatment in the adenine-CKD model, while development
of microhemorrhages appeared to be independent of hy-
pertension. The latter finding was consistent with our
MRI studies of microbleeds in humans. Cell culture stud-
ies demonstrated significant impairment of the brain en-
dothelial barrier upon exposure to uremic serum, with up
to 65% drop in TEER in the 15% CKD serum group.
Incubation with increasing concentrations of urea, the
most abundant retained toxin in CKD [29], demonstrated
disruption of the actin cytoskeleton and decreased tight
junction proteins as potential mechanisms to explain the
endothelial barrier dysfunction.
CKD has an impact on cerebrovascular disease risk that
appears to go well beyond traditional risk factors such as
hypertension and diabetes [10, 11]. Brain microbleeds are
present in up to 50% of patients with advanced CKD
[2–4] and correlate with cognitive dysfunction [4, 8,
19–23] and increased risk of hemorrhagic stroke [9]. Our
group recently proposed CKD-specific pathways that could
promote cerebral small vascular disease via disruption of
blood flow autoregulation and BBB integrity, such as in-
creased vascular calcification, systemic inflammation, and
uremic toxins [1]. Our tissue culture studies demonstrate that
exposure to urea in concentrations similar to those present in
dialysis patients produced reduced expression of tight junc-
tion protein claudin-5 and disruption of the actin cytoskele-
ton. These pathways appear to explain, at least in part, the
increased microhemorrhages due to increased BBB perme-
ability observed in the CKD animals and patients. Of note,
CKD has previously been associated with a marked deple-
tion of tight junction proteins (75–80% decreased expres-
sion) in gut epithelial cells from experimental animals [30].
Subsequent in vitro studies revealed the central role of urea
in the CKD-induced disruption of intestinal epithelial barrier
structure and function [28]. Taken together, these
observations suggest that urea toxicity is not limited to
endothelial cells alone. Our data add to the growing body
of evidence for direct adverse effects of uremic toxins on
the vascular endothelium; other groups have reported that
the gut-derived bacterial metabolites indoxyl sulfate and
p-cresyl sulfate induce oxidative stress in cultured endo-
thelial cells [31, 32].
LPS is an established acute inflammatory stimulus used in
rodent models [33] that binds to toll-like receptor 4 [34] to
induce BBB damage [35] and brain endothelial dysfunction
[36, 37]. LPS has been used to amplify and study microbleeds
pathophysiology in young adult and aged mice [25, 26, 38]. In
our current animal studies, LPS treatment increased
microhemorrhage formation to the same degree in CTL and
CKD animals, by approximately 2-fold (Table 1; Fig. 2a). In
CTL mice, average microhemorrhage count was increased
from 2 to 3.6 per cm2 with LPS, whereas in CKD mice, the
increase was from 4.5 to 10.3 per cm2. We conclude that the
uremic brain is predisposed to more severe injury after an
acute inflammatory event due to pre-existing injured BBB.
The actin cytoskeleton reversibly polymerizes between
globular (G-actin) and filamentous (F-actin) configurations.
F-actin is important for cell adhesion, division, and apopto-
sis; it is modulated by actin-binding proteins, which are in
turn regulated by Rho GTPases [39, 40]. Actin reorganiza-
tion, from its cortical distribution into stress fibers, is a key
component of the endothelial response to inflammation [41].
Our cell culture studies implicated elevated urea in the path-
ogenesis of decreased F-actin expression, with fragmentation
of cortical fibers and appearance of radial stress fibers (Fig.
4c). Further studies are needed to clarify the role of actin
cytoskeletal disruption in microbleeds pathophysiology
in vivo.
Although hypertension is a strong predictor of cerebral
microbleeds in the general population [42], we found that hyper-
tension did not modify presence of microbleeds in our CKD
animal and human subjects (Tables 1 and 2). Our study is limited
by small sample size; however, our results are consistent with
prior cross-sectional reports in which CKD was a risk factor for
brain microbleeds, independent of hypertension, age, and diabe-
tes mellitus [10, 11]. The degree of hypertension in the 5/6 ne-
phrectomy animals was mild; however, our findings are consis-
tent with the study by Passos et al. in which induction of signif-
icant hypertension in wild-type mice via infusion of angiotensin
II and L-NG-nitroarginine methyl ester (systolic 180 mmHg) did
not significantly raisemicrohemorrhage counts [43].While prev-
alence of brain microbleeds was similar in the two CKD patient
groups (approximately 50%), analysis of consecutive brain
MRIs demonstrated microbleed progression in three of four he-
modialysis patients as compared to zero of four pre-dialysis pa-
tients (follow-up interval of ~ 1.5 years). Hemodialysis patients
may be particularly predisposed to microbleed formation due to
inter- and intradialytic BP fluctuations, regional gut ischemia
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leading to increased endotoxin translocation (which drives sys-
temic inflammation), and use of heparin anticoagulation during
dialysis therapy [1, 44, 45].
The major limitation of our cell culture work is the
use of an immortalized cell line, with known limitation
of brain-specific properties [46]. Further cell culture
studies using, for example, primary brain endothelial
cells are needed to confirm our findings. Our human
study, a retrospective analysis of patients with serial
brain MRIs, has the limitations of patient identification
using hospital database diagnosis and procedure codes
and of small sample size.
In summary, CKD increased brain microbleeds in both hy-
pertensive and non-hypertensive mouse models. Uremic se-
rum, and urea alone, disrupted the cultured brain endothelial
cell monolayer, thus supporting a mechanistic role for uremic
toxins affecting BBB permeability and promoting
microhemorrhages. Human brain MRI studies confirmed in-
creased prevalence of microbleeds in CKD patients compared
with age-matched non-CKD controls, and hemodialysis pa-
tients in particular were noted to develop new microbleeds
over a 1.5-year follow-up period. More studies are warranted
to further characterize factors in the CKD milieu that promote
brain microhemorrhages.
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